Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Indivior (NASDAQ:INDV) Edges 6% Higher Pre-Market Today as Q3 Profit Tops Estimates and Guidance Holds

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) shares rose in pre-market trading after the company reported third-quarter results before the open. Adjusted earnings per share of $1.32 were above estimates that varied by data provider between $0.80 and $1.12. Revenue of $356.0 million was about 8% above …

Nitish Kishor | 29 October 2026

Why Insmed (NASDAQ:INSM) Is Up 14% Pre-Market Today: Brinsupri Launch Lifts the Floor Under 2026 Sales Guidance

Insmed Incorporated (NASDAQ:INSM) shares surged in pre-market trading after third-quarter results showed revenue of $524.4 million, about 5% above the market estimate of roughly $500 million. The adjusted loss of $0.46 per share was wider than the $0.34 loss the market expected, but attention …

Nitish Kishor | 29 October 2026

Iovance (NASDAQ:IOVA) Falls 26% Pre-Market Today as Lung Cancer Data Fail to Hold Overnight Rally

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares fell sharply in pre-market trading after the company published updated Phase 2 results for lifileucel in previously treated non-squamous metastatic non-small cell lung cancer. The shares had risen 11% to 12% in late Wednesday trading on the announcement of …

Nitish Kishor | 29 October 2026

Q3 Beat and Higher Guidance Lift Novocure (NASDAQ:NVCR) 3% Pre-Market Today

Novocure Ltd (NASDAQ:NVCR) shares moved higher in pre-market trading after the company posted a third-quarter loss of $0.09 per share, well inside the $0.21 to $0.24 loss the market had expected. Revenue of $193.4 million was about 6% above the roughly $182 million estimate …

Nitish Kishor | 29 October 2026

Teladoc Health (NYSE:TDOC) Jumps 13% Pre-Market Today After Narrower Loss and Higher 2026 Outlook

Teladoc Health, Inc. (NYSE:TDOC) shares climbed in pre-market trading after a third-quarter report that topped expectations on revenue and showed a narrower loss. Revenue of $605.1 million fell about 3% from a year earlier but landed near the high end of company guidance. The …

Nitish Kishor | 29 October 2026

Viking Therapeutics (NASDAQ:VKTX) Slips 3% Pre-Market Today as Wider Q3 Loss Meets Longer Launch Timeline

Viking Therapeutics, Inc. (NASDAQ:VKTX) shares edged lower in pre-market trading after third-quarter results showed a net loss of $183.2 million, or $1.55 per share, wider than the loss of $1.00 to $1.06 the market expected. Research and development expense was $166.8 million, up from …

Nitish Kishor | 29 October 2026

Axogen, Inc. (NASDAQ:AXGN) Jumps as Revenue Growth Prompts a Raised Outlook

● Quarterly revenue rose 26.2% year over year, beating modest prior expectations.

Nitish Kishor | 29 October 2026

Beta Bionics (NASDAQ:BBNX) Falls on Revenue Timing Despite Sales Growth

● The decline did not stem from weak underlying demand.

Nitish Kishor | 29 October 2026

Bicara Therapeutics (NASDAQ:BCAX) Slides Sharply Without a Confirmed Explanation

● No confirmed company-specific catalyst was identified behind the drop.

Nitish Kishor | 29 October 2026

Beam Therapeutics (NASDAQ:BEAM) Surges Amid a Biotech Sentiment Wave

● No confirmed company-specific catalyst was identified behind the move.

Nitish Kishor | 29 October 2026
Support

Hi! How can we help you today?

Loading…